RESOLVED, IPO opposes The Interagency Patent Coordination and Improvement Act of 2023 (S.79), and any substantively similar legislation that would provide the USPTO with access to a patent applicant’s confidential regulatory submissions to the FDA.
RESOLVED, IPO opposes The Interagency Patent Coordination and Improvement Act of 2023 (S.79), and any substantively similar legislation that would provide the USPTO with access to a patent applicant’s confidential regulatory submissions to the FDA.